retatrutide peptide triple hormone receptor agonist Medscape | Retatrutide, Eli Lilly's first-in-class agonist, delivered meaningful weight loss at 80 weeks in all doses in the Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces

Description

Miller-Materos large study confirms prior evidence, from Tufvesson-Alm and colleagues, regarding the role of the gutbrain axis in alcohol use

Clinically significant weight loss for many people while on the medicine Better metabolic health, including improved A1c (a blood test that shows your average blood sugar level over the past two-to-three months), blood pressure and cholesterol for appropriate patients A non-surgical approach you can start with medical supervision Combining Bariatric Surgery and GLP-1s Some people use GLP-1 medications before surgery to improve readiness (i.e., better control over conditions such as diabetes) and after surgery to manage plateaus or weight regain

Its the early testing edge that has Regeneron excited about Hansohs HS-20094, since the drug has already been studied in over 1k patients, leading Regeneron to claim it has a potentially similar profile to Lillys popular GLP-1/GIP agonist